Sign In
Buy ARGX
$813.14
+10.97 (+1.37%)
At Close: Jun 03, 2026
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q1 2022 Results - Earnings Call Transcript
07:38pm, Saturday, 07'th May 2022
argenx SE (NASDAQ:ARGX ) Q1 2022 Earnings Conference Call May 5, 2022 8:30 AM ET Corporate Participants Beth DelGiacco - VP Corporate Communications and Investor Relations Tim Van Hauwermeiren - Chief
argenx SE (ARGX) Q1 2022 Earnings Call Transcript
12:30pm, Friday, 06'th May 2022 The Motley Fool
ARGX earnings call for the period ending March 31, 2022.
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
12:43pm, Thursday, 05'th May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
FDA Approval For AstraZeneca-Daiichi's Enhertu Expands To Earlier Use In Metastatic Breast Cancer
The�
Argenx's Vyvgart Meets Primary Goal In Late-Stage Bleeding Disorder Study
11:11am, Thursday, 05'th May 2022
Argenx SE's (NASDAQ: ARGX) Phase 3 ADVANCE trial of Vyvgart (efgartigimod alfa-fcab) in adults with primary immune thrombocytopenia (ITP) met its primary endpoint. The ADVANCE trial enrolled 131 a
argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia
05:00am, Thursday, 05'th May 2022 GlobeNewswire Inc.
Study met primary endpoint, demonstrating a higher proportion of sustained platelet response with VYVGART treatment compared to placebo (p=0.0316); responders observed across patient types regardless
argenx Reports First Quarter 2022 Financial Results and Provides Business Update
05:00am, Thursday, 05'th May 2022 GlobeNewswire Inc.
May 5, 2022
argenx to Present at BofA Securities 2022 Healthcare Conference
05:00am, Wednesday, 04'th May 2022 GlobeNewswire Inc.
May 4, 2022Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announce
argenx to Present at BofA Securities 2022 Healthcare Conference
01:00am, Wednesday, 04'th May 2022
May 4 , 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announ
Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2022
02:04pm, Tuesday, 03'rd May 2022 Benzinga
Upgrades
For SVB Financial Group (NASDAQ:SIVB), Oppenheimer upgraded the previous rating of Perform to Outperform. For the first quarter, SVB Finl Gr had an EPS of $7.92, compared to year-ago quarter
argenx to Report First Quarter 2022 Financial Results and Business Update on May 5, 2022
01:00am, Thursday, 28'th Apr 2022
April 28, 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today anno
Halzoyme (HALO) Up 8.3% YTD: Will It Continue to Trend Higher?
02:22pm, Friday, 22'nd Apr 2022 Zacks Investment Research
Halozyme's (HALO) revenues are driven by strong demand for new partnered drugs. Restructuring initiatives are boosting margins. Robust revenue growth is expected to continue in 2022.
This is what you should do in the stock market now, according to three 2022 fund-award winners
01:18pm, Saturday, 09'th Apr 2022 MarketWatch
Don't get out of equities and start to favor growth strategies.
Halozyme's (HALO) ENHANZE Drives Sales Amid Rising Competition
12:24pm, Wednesday, 06'th Apr 2022 Zacks Investment Research
Halozyme (HALO) is attracting partnerships from several large pharma companies as well as biotechs, courtesy of its ENHANZE technology. Royalties and product supply to partners are likely to drive rev
The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel
11:48am, Tuesday, 05'th Apr 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Theravance Announces Phase 3 Data For Ampreloxetine Showing Clear Benefit In Multiple System Atrophy P
